adminJoshua Disbrow
CEO & Director
I’m Josh Disbrow Co-Founder and Chief Executive Officer of Aytu. And it’s my pleasure to welcome you to Aytu Biopharma’s first ever Investor Day. Welcome to all those here joining us in-person in New York City, and welcome also to all of those joining via the webcast, great to have you all here. It’s an exciting day for Aytu having just announced the formal and official launch of Exxua just this morning prior to the market open, really a thrilling time in the company’s history as we look at this transformational time and this transformational opportunity that we have as we think about the launch of Exxua, the first and only 5-HT1a agonist and truly a first-in-class treatment for major depressive disorder.
Excited to let you know that we’re — we’ve got the sales force now fully deployed. We’re actually out there generating prescriptions as we speak, having already generated a significant number of prescriptions and hearing a lot of enthusiasm from the field. It’s truly a unique opportunity for us as Aytu as we think about the opportunity that is Exxua.
Before we get started, some housekeeping items and the obligatory forward-looking statements. Just a reminder that some of us that will be speaking today may be making some forward-looking statements as we progress through the discussion.
Further, I’ll refer you to Aytu Biopharma’s
Read the full article here
